CDMRP & Defense Health Program Medical Research Funding Opportunities

MHSRS Breakout Session
August 4, 2026
1300-1500

DHA Defense Health Agency ®

CDMRP DEPARTMENT OF WAR CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

DSIP Defense SBIR/STTR Innovation Portal Proposal Submissions

SBIR·STTR America's Seed Fund™ POWERED BY SBA

Disclaimer: The views and opinions expressed in this session's presentations are those of the authors and do not reflect official policy or position of the Defense Health Agency, Department of War, or the U.S. Government

Disclosures: The presenters in this session have no conflicts of interest to report

- Congressionally Directed Medical Research Programs
- Defense Health Programs Science & Technology
- Small Business Innovation Research/Small Business Technology Transfer Programs
- Defense Health Agency Contracting Activity
- Panel Q&A

Funding Your Research Pipeline

Strategically leverage multiple sources of funding and resources to facilitate success

Congressionally Directed Medical Research Programs FY 2026 Overview

COL Mark Hartell, CDMRP Director

August 4, 2026

Defense Health Agency
RESEARCH & DEVELOPMENT ®

Disclaimer

The views, opinions, and/or findings contained in this presentation are those of the author and do not necessarily reflect the views of the Department of War and should not be construed as an official DOW/Army position, policy, or decision unless so designated by other documentation. No official endorsement should be made. Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the U.S. Government.

About the CDMRP

Mission

Responsibly manage collaborative research that discovers, develops, and delivers health care solutions for Service Members, their Families, Veterans, and the American public



https://cdmrp.health.mil

About the CDMRP – Hallmarks

IMPACT

- Funds impactful, innovative research for specific programs added by Congress to the Defense Appropriations Bill
- Targets research to fills gaps and address high-priority needs
- Focuses on improving health, well-being, and health care quality for those affected

STRATEGY

- Annually adapts each program's vision and investment strategy, allowing rapid response to changing needs, opportunities, and congressional intent
- Publicly announces and competes funding opportunities
- Ensures scientific excellence and programmatic relevance through the National Academy of Medicine-recommended two-tier review process

Hallmarks, cont'd

COLLABORATION

- Integrates consumers as full participants throughout program processes and as the "True North" of the CDMRP
- Collaborates with other funding organizations – complementary, not duplicative

STEWARDSHIP

- Obligates funds up front; limited out-year budget commitments
- Maximizes funding available for research through low management costs and efficient processes
- Maintains transparency and accountability

Pathways to Health Care Solutions

Congressional Intent

Specific targeted research areas and guidance

Capability Gaps and Requirements

Identified military needs for the Warfighter

CDMRP

CONGRESSIONAL SPECIAL INTEREST
DEFENSE HEALTH PROGRAM
RDTE FUNDING

Strategic priorities / gaps

Research discoveries / results

DOW Core Research Programs

DEFENSE HEALTH PROGRAM
AND SERVICES FUNDING

HEALTH CARE SOLUTIONS

for Service Members, their Families, Veterans, and the American Public

Shared Benefits

PRODUCTS

Fielded Medical Knowledge	Fielded Medical Materiel
Medical knowledge products, such as software algorithms or clinical practice guidelines	*Tangible products, such as vaccines, drugs, biologics, and medical devices*

CDMRP FY 2026 Appropriations

Research Program	FY 2026 $M	Research Program	FY 2026 $M
Alcohol and Substance Use Disorders	$4.0	Neurofibromatosis	$25.0
Alzheimer's	$15.0	Orthopaedic	$20.0
Amyotrophic Lateral Sclerosis	$40.0	Ovarian Cancer	$50.0
Arthritis	$10.0	Pancreatic Cancer	$20.0
Autism	$8.0	Parkinson's	$16.0
Bone Marrow Failure	$7.5	Peer Reviewed Cancer, *20 topics*	$165.0
Breast Cancer	$145.0	Peer Reviewed Medical, *52 topics*	$370.0
Combat Readiness Medical	$5.0	Prostate Cancer	$75.0
Duchenne Muscular Dystrophy	$12.5	Rare Cancers	$17.5
Epilepsy	$12.0	Reconstructive Transplant	$12.0
Hearing Restoration	$5.0	Spinal Cord Injury	$33.0
Joint Warfighter Medical	$10.0	Tick-Borne Disease	$7.0
Kidney Cancer	$15.0	Toxic Exposures	$15.0
Lung Cancer	$20.0	Traumatic Brain Injury and Psychological Health	$40.5
Lupus	$10.0	Tuberous Sclerosis Complex	$10.0
Melanoma	$40.0	Vision	$10.0
Military Burn	$10.0	**TOTAL**	**$1.27B**
Multiple Sclerosis	$15.0		

FY26 Research Programs
$1.27B Appropriated

Defense Health Agency
RESEARCH & DEVELOPMENT

CDMRP
DEPARTMENT OF WAR
CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

Cancer

Breast Cancer
Kidney Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Peer-Reviewed Cancer, 20 topics
Prostate Cancer
Rare Cancers
*Toxic Exposures **

Neuroscience/ Neurodegeneration

Alcohol and Substance Use Disorders
*Alzheimer's **
*Amyotrophic Lateral Sclerosis **
Autism
*Epilepsy **
*Hearing Restoration **
*Joint Warfighter Medical **
*Multiple Sclerosis **
*Neurofibromatosis **
Parkinson's
*Spinal Cord Injury **
*Toxic Exposures **
*Traumatic Brain Injury and Psychological Health **
*Tuberous Sclerosis Complex **
Vision
Peer Reviewed Medical ⁋

Autoimmune Disorders and Immunology

Arthritis
*Bone Marrow Failure **
Lupus
*Multiple Sclerosis **
*Reconstructive Transplant **
Peer Reviewed Medical ⁋

Trauma/Injury and Orthopaedic Medicine

*Alzheimer's **
*Combat Readiness-Medical **
*Epilepsy **
*Hearing Restoration **
*Joint Warfighter Medical **
*Military Burn **
Orthopaedic
*Reconstructive Transplant **
*Spinal Cord Injury **
*Toxic Exposures **
*Traumatic Brain Injury and Psychological Health **
Vision
Peer Reviewed Medical ⁋

Infectious Diseases

*Combat Readiness Medical **
*Joint Warfighter Medical **
*Military Burn **
Tick-Borne Disease
Peer Reviewed Medical ⁋

Internal Medicine, Cardiovascular, and Respiratory Health

*Military Burn **
*Toxic Exposures **
Peer Reviewed Medical ⁋

Rare Diseases and Conditions

*Amyotrophic Lateral Sclerosis **
*Bone Marrow Failure **
*Duchenne Muscular Dystrophy **
*Neurofibromatosis **
*Tuberous Sclerosis Complex **
Peer Reviewed Medical ⁋

**** Programs cover a range of research areas***
⁋ Peer Reviewed Medical includes 52 topics that span research areas

CDMRP Military Relevance

- Every program aligns with CDMRP's overarching vision of transforming health care for Service Members, their Families, Veterans, and the American public

Select examples of incidence in the military:

- Service Members are at a 50% greater risk for ALS
- Compared with civilians, deployed Service Members are twice as likely to suffer a burn injury
- Female Service Members 40-59 years of age have a higher incidence rate of breast cancer
- Substance abuse responsible for ~30% of Army's suicide deaths
- Deployment associated with 1.8-fold increased risk of Parkinson's
- Risk of dementia is 2-4 times higher in Service Members; increases by 70% following a TBI
- Military aviators have an 87% higher rate of melanoma compared to a demographically similar U.S. population

- Commitment to the health and well-being of DOW Families also directly contributes to the readiness of Service Members by allowing them to focus on their military mission
  - Over 15,000 military dependents have a diagnosis of autism spectrum disorder
  - Over 43,000 beneficiaries affected by epilepsy in 2024

Congressionally Directed Medical Research Programs

Program Cycle Overview

Kathryn Argue, Ph.D., CDMRP Program Manager

August 4, 2026

Defense Health Agency
RESEARCH & DEVELOPMENT ®

Program Cycle



Vision Setting

Every CDMRP program develops an investment strategy, considering strategic drivers such as:

- Congressional language
- Input and guidance from senior leaders and the programmatic panel, which includes consumers, who are patients, care providers, and families
- Current research landscape, including federal and non-federal funders
- Research, capability, and clinical gaps
- Emerging technologies
- Impact
- Portfolio composition

CDMRP Award Mechanisms

- Funding opportunities are program announcements or program-specific broad agency announcements
  - Grants/cooperative agreements; few contracts/other transactions
- Numerous types of award mechanisms
  - Tailored to the goals of each program
  - Programs, topics, and focus areas may vary from year to year
  - Fund the full continuum of research

Initial Concepts

- Concept
- Discovery
- Exploration–Hypothesis Development

Early and Maturing Ideas

- Idea
- Idea Development
- Investigator-Initiated

Pre-Clinical and Translational

- Translational Research
- Technology/ Therapeutic Development

Clinical

- Clinical Trial
- Clinical Research
- Outcomes Research

Team Science

- Consortium
- Focused Program
- Translational Partnership

Research Capacity

- Virtual Academy/ Center
- New Investigator
- Early Career

Funding Opportunities

- Pre-announcements and funding opportunity release notifications
  - CDMRP website and email blasts
- Funding opportunity postings
  - CDMRP website, cdmrp.health.mil
  - Grants.gov, CFDA 12.420
  - electronic Biomedical Research Application Portal system, eBRAP.org
- Quickly find open CDMRP funding opportunities on the CDMRP website here:

Goal of the Two-Tier Review Process

To develop funding recommendations that balance ***the most meritorious science*** and offer the highest promise to ***fulfill the programmatic goals*** set forth in the funding opportunity

Peer Review

- Criterion-based evaluation of full proposal
- Determination of "absolute" scientific merit
- **Outcome: Summary Statements**
  - No standing panels; programs recruit reviewers based on expertise needed
  - No contact between applicants, reviewers, and program staff

Partnership

Programmatic Review

- Comparison among proposals of high scientific merit
- Determination of adherence to intent, program relevance, and potential for impact
- **Outcome: Funding Recommendations**
  - No "pay line"; consider portfolio balance
  - Funds obligated up front; limited out-year budget commitments, but milestones imposed
  - No continuation funding

Additional information available at: https://cdmrp.health.mil/about/2tierRevProcess

Consumers are the "True North" and Foundation of the CDMRP

The CDMRP includes consumers – patients, survivors, family members, and/or caregivers – in every aspect of the program lifecycle.

Consumers serve as full voting members on peer review and programmatic panels.

Through their lived experiences, consumers add valuable perspectives, a sense of urgency, and important input to the program mission, investment strategy, and research focus.

Program Lifecycle	FY 2024-2025 Consumer Involvement
Stakeholder Meeting	**124** consumers* served as programmatic panel members and ad hoc reviewers representing over **107** consumer advocacy organizations, Service Members, or Veterans
Vision Setting	
Pre-App Screening	
Peer Review	**1,454** consumer reviewers** assigned to panels, nominated by over **340** consumer advocacy organizations
Programmatic Review	
Funding Recommendations	
Award Execution	**32** funding opportunities that incorporate consumer participation in the research project
Awards Management/ Closeout	

* All unique individuals
** 1,304 unique individuals

Peer Reviewed Medical Research Program

Vision: Improve the health, care, and well-being of all military Service Members, Veterans, and their Families

Mission: Encourage, identify, select, and manage medical research projects of clear scientific merit that lead to impactful advances in health care of Service Members, Veterans, and their Families



- Initiated in 1999 to address diseases and conditions with relevance to military health
- Direction from congress to support research of “clear scientific merit” and “direct relevance to military health” in specified Topic Areas

PRMRP Investment Strategy Process

Congression Appropriation $370M CSI

Congressionally Directed Topic Areas

Topic Areas allocated into PRMRP Portfolios

- Autoimmune Disorders and Immunology
- Cardiovascular Health
- Infectious Diseases
- Internal Medicine
- Neuroscience and Mental Health
- Orthopaedic Medicine
- Rare Diseases and Conditions
- Research and Clinical Tools
- Respiratory and Environmental Health

Targeted Funding

Strategic Goals
- Foundational
- Epidemiology
- Prevention
- Diagnosis
- Treatment

Input from stakeholders

Funding Opportunities



- ✓ **Funding decisions based on scientific merit**
- ✓ **No pre-allocation of funds to Topic Areas or Portfolios**

FY 2026 PRMRP Portfolios

Autoimmune Disorders and Immunology

- Celiac Disease
- Eczema
- Food Allergies
- Inflammatory Bowel Disease
- PANS and PANDAS*
- Sarcoidosis
- Scleroderma

Cardiovascular Health

- Brain Injury Impact on Cardiac Health*
- Hypoxia*

Infectious Diseases

- Congenital Cytomegalovirus
- Hepatitis B
- Tuberculosis

Internal Medicine

- Accelerated Aging Processes Associated with Military Service*
- Endometriosis
- Hypertrophic Dyschromia
- Infertility Associated with Military Aviators and Aviation
- Interstitial Cystitis
- Pancreatitis
- Polycystic Kidney Disease

Orthopaedic Medicine

- Accelerated Aging Processes Associated with Military Service*
- Musculoskeletal Health
- Orthotics and Prosthetics Outcomes

Neuroscience and Mental Health

- Brain Injury Impact on Cardiac Health*
- Dystonia
- Eating Disorders
- Gambling Addiction
- Hydrocephalus
- Intranasal Ketamine Anesthetics
- Maternal Mental Health
- Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome
- PANS and PANDAS*
- Peripheral Neuropathy
- Post-Traumatic Stress Disorder
- Sleep Disorders and Restrictions
- Suicide Prevention

Rare Diseases and Conditions

- Angelman Syndrome
- Ehlers-Danlos Syndrome
- Facioscapulohumeral Muscular Dystrophy
- Fibrous Dysplasia/ McCune-Albright Syndrome
- Fragile X
- Frontotemporal Degeneration
- Hereditary and Acquired Ataxia
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Hermansky-Pudlak Syndrome
- Mitochondrial Disease
- Myotonic Dystrophy
- Prader-Willi Syndrome
- Rett Syndrome
- Sickle Cell Disease
- Spinal Muscular Atrophy
- von Hippel-Lindau Disease

Respiratory and Environmental Health

- Burn Pit Exposure
- Hypoxia*
- Pulmonary Fibrosis
- Respiratory Health

Research and Clinical Tools

- Proteomics

Topic occurs in more than one portfolio

FY 2026 PRMRP Award Mechanisms

Basic Research

Discovery Award
- Novel/breakthrough exploratory research, beyond incremental advances
- High-risk/high-reward
- No preliminary data

Research Advancement Award
- Preclinical expansion, replication, comparative studies to validate preliminary or published data
- Preliminary data required

Translational Research

Impact Award
- Mature research studies, beyond incremental advances
- Potential near-term clinical impact for patients
- Seeks to translate preclinical findings into a clinical application
- Strong in vivo preliminary data required

Technology/Therapeutic Development Award
- Final steps of clinical translation for validated findings
- IND-/IDE-enabling studies
- Post-IND/-IDE studies required to transition a product or prototype utility
- Strong preliminary data demonstrating product or prototype utility required

Clinical Trials/ Clinical Research

Clinical Trial Award
- Measures safety, effectiveness, efficacy outcomes of an intervention in humans
- Early-phase or large-scale interventional clinical trials

Lifestyle and Applied Health Research Award
- Clinical trials for nonpharmacological therapies or noninvasive devices
- Clinical research focused on patient outcomes and quality of life

Platform Clinical Translation Award
- Finalizing preclinical development, conducting clinical validation and/or conducting first-in-human trials for platform product
- Must address two or more PRMRP topic areas

Products Developed with the Help of PRMRP Funding

Cobas® Liat® "Laboratory in a Tube" PCR System

Point-of-care device for PCR-based diagnosis of infectious diseases

FY 2004: $1.9M to IQuum, Inc.

- ✓ Development of a rapid, deployable test for infectious diseases
- ✓ $50M additional federal funding
- ✓ Currently sold by Roche

Initial FDA approval in 2011

Butterfly iQ Portable Ultrasound

Portable ultrasound links to smart phone for point-of-care assessment and diagnosis. Equipped for use in austere environments

FY 2001: $2.0M to GE Research

- ✓ Array development and preliminary human safety testing
- ✓ Patents incorporated into several Butterfly devices

Received FDA approval in 2017

VAZALORE® Aspirin-Lipid Formulation

Liquid-filled aspirin-omega-3-phosphatidylcholine capsules with reduced gastrointestinal side effects

FY 2004: $1.8M to the University of Texas Health Science Center at Houston

- ✓ Preclinical testing in rodent models

Received FDA approval in 2021

Planning for Post-Award Transition to Advance a Potential Product

Strategy & Planning	» Continuously update project plan » Define milestones & regulatory pathway
Evidence & Data	» Identify required data for the next phase » Maximize existing resources to generate the data set
Partnerships & Funding	» Explore aligned funding opportunities » Form collaborations for the next phase
Implementation & Expansion	» Outline plan to deliver the product to users » Consider alternate users to broaden collaborations and funding possibilities

Congressionally Directed Medical Research Programs

Toxic Exposures Research Program

Angel Davey, Ph.D., CDMRP Program Manager

August 4, 2026

Defense Health Agency
RESEARCH & DEVELOPMENT ®

Toxic Exposures Research Program

Vision

Improve the health and quality of life, and mitigate risks for those impacted by military-related toxic exposures

Mission

Fund research to understand and provide solutions to prevent, diagnose, and treat the health outcomes associated with military-related toxic exposures impacting Service Members, Veterans, their Families and the public

- **First Appropriation Fiscal Year (FY) 2022**: $30M
- **Total Appropriations (FY22-FY25):** $105M
- **FY26 Appropriation:** $15M

https://www.dvidshub.net/image/6015652/gulf-war-deployment
https://www.dvidshub.net/image/1025646/flurry-foam-released-travis
https://www.dvidshub.net/image/80303/supplying-medical-mission
https://www.dvidshub.net/image/6621582/chinook-refuel

For more information, please visit: https://cdmrp.health.mil/terp

FY26 TERP Goals and Topic Areas

Program Goals

- **Predict and Prevent:** Identify strategies that can anticipate, identify, monitor and prevent adverse effects of exposures to toxic substances
- **Diagnose**: Understand the clinical signs, symptoms and outcomes associated with exposures and predict disease progression to develop specific or improved diagnostics
- **Treat:** Minimize symptoms and disease progression associated with exposures

Topic Areas



Neurotoxin Exposure

Gulf War Illness and Its Treatment

Airborne Hazards and Burn Pits

Other Military Service-Related Toxic Exposures in General, Including Prophylactic Medications, Pesticides, Organophosphates, Toxic Industrial Chemicals, Materials, Metals and Minerals

For more information, please visit: https://cdmrp.health.mil/terp

FY26 TERP Additional Guidance

Studies focused on the following areas do NOT meet the intent of the FY26 TERP*:*

- Research data that are classified and/or research in which anticipated outcomes may be classified or deemed sensitive to national security concerns
- Chemical warfare agents categorized as fourth-generation agents or non-traditional agents
- Biological Select Agents or Toxins
- Anomalous Health Incidents (Havana Syndrome)
- Directed energy weapons
- Development of medical countermeasures or devices intended to diagnose, detect, prevent, or treat the immediate, i.e., point of injury, health effects of chemical weapons, biological, radiological, or nuclear threats
- Treatments or therapeutics for the immediate, adverse health effects of any exposure that would be administered in an acute care setting, i.e., role of care (ROC) 1 or ROC 2
    - ROC 1: Unit-level medical care, ranging from point of injury through battalion aid station
    - ROC 2: Advanced trauma management and emergency medical treatment

FY26 TERP Funding Mechanisms

Maturing Ideas	Mechanism	Intent	Funding Amount
	**Investigator Initiated Research Award** Independent investigators; all career levels	Supports studies that will make an important contribution to research and/or patient care for a disease or condition associated with military-related toxic exposures. May include preclinical studies in animal models and human subjects	**Maximum allowed funding:** **$800,000 total costs*** **Maximum period of performance (POP) is 3 yrs**

Translational	Mechanism	Intent	Funding Amount
	**Translational Research Award** Independent investigators; all career levels Partnering Option: Up to 2 principal investigators; separate awards for one total cost	Supports **translational research** to accelerate promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines	**Maximum allowed funding:** **$1,500,000 total costs*** **Maximum POP is 3 yrs**

Clinical	Mechanism	Intent	Funding Amount
	**Clinical Trial Award** Independent investigators; all career levels Partnering Option: Up to 2 principal investigators; separate awards for one total cost	Supports **clinical trials** with potential to significantly impact prevention, treatment or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures	**Maximum allowed funding:** **$4,500,000 total costs*** **Maximum POP is 4 yrs**

*direct + indirect costs

FY26 TERP Funding Mechanisms

Requirements

» Address at least one Program Goal **and** at least one Topic Area

» "TERP Additional Guidance" - What does/does not meet program intent

» Adhere to total cost limits; all applications will be funded with FY26 funds

Partnerships and Collaborations

» TRA and CTA Partnering Option - Supports up to 2 Principal Investigators via separate awards for one total cost

» Collaboration with DOD and/or VA researchers and clinicians is encouraged (but not required)

» Additional CTA-specific encouragements:

- Participation of at least one military or Veteran consumer on the research team
- Recruitment of relevant military and/or Veteran population(s)

Preproposal due:
August 19, 2026

↓

Full Application Due:
November 19, 2026

↓

Peer Review:
January 2027

↓

Programmatic Review:
March 2027

Plan for Access and Approvals

- Military or Veteran patient populations and resources, such as databases, specimens, etc.
  - Clearly define DOW or VA collaborator role: Conducting research may require higher level approval
    - Key collaborators should include research partners and publication co-authors
    - Plan for IRB review
    - Create a contingency plan if PI is military, as many move every few years
- Know the legal instruments available for collaborative research, e.g., Cooperative Research and Development Agreement, Memorandum of Understanding, Material Transfer Agreement
- Know the requirements and timelines for human or animal subjects research approvals and consult early when planning collaboration

Guidance for Conducting Human Subjects Research with DOW Affiliated Personnel or Military Beneficiaries

Military Relevance in Your Project

- Consider how to tailor your research to benefit military health and the broader public
  - Highlight similarities between military and civilian injuries/conditions
- Consider impacts to Family members and Veterans in addition to Service Members
  - Readiness includes family members
- Understand roles of care in DOW and your intended use environment
  - Fielded, en route, hospital
- Use validated and relevant models or populations that are aligned with program goals
  - No requirement to use military populations

Congressionally Directed Medical Research Programs

Orthopaedic Research Program

Akua Roach, Ph.D., CDMRP Program Manager

August 4, 2026

Defense Health Agency
RESEARCH & DEVELOPMENT ®

Orthopaedic Research Program

Vision:
Provide all Service Members with orthopaedic injuries the opportunity for optimal recovery and restoration of function

Mission:
Fund high impact and clinically relevant research to advance treatment and rehabilitation from orthopaedic injuries sustained during combat and service-related activities to maximize return to duty

History

- **First Appropriation Fiscal Year (FY)2009**: $112M
- **Total appropriations FY09-FY24**: $548.5M
- **FY26 Appropriation**: $20M

FY26 Focus Areas

- Battlefield Fracture-Related Infection
- Composite Tissue Regeneration
- Ligamentous Trauma
- Limb Stabilization and Protection
- Osteointegration Outcomes
- Return-to-Duty Strategies
- Military Women's Health

For more information, please visit: https://cdmrp.health.mil/orp/

ORP FY26 Funding Mechanisms

Maturing	Mechanism	Focus Areas	Funding Amount
	**Applied Research Award** Supports applied research focused on advancing optimal treatment and restoration of function after orthopaedic injury	Battlefield Fracture-Related Infection Composite Tissue Regeneration Limb Stabilization and Protection Osseointegration Outcomes Return-to-Duty Strategies	**Maximum allowed funding:** $950,000 total costs Maximum Period of Performance (POP) is 3 yrs

Clinical	Mechanism	Focus Areas	Funding Amount
	**Clinical Research Award** **Research Level 1: Clinical Research** Supports projects that demonstrate potential to impact the standard of care, both immediate and long-term, as well as contribute to evidence-based guidelines for the evaluation and care of Service Members, Veterans, and all patients with orthopaedic injuries. **Research Level 2: Clinical Trials** Supports projects that demonstrate potential to have impact on the treatment or management of military combat or service-related orthopaedic injuries that significantly improve unit readiness and return-to-duty/work rates	**Research Level 1** Ligamentous Trauma Osseointegration Outcomes Return-to-Duty Strategies Military Women's Health **Research Level 2** Ligamentous Trauma Limb Stabilization and Protection Return-to-Duty Strategies	**Maximum allowed funding:** **Research Level 1** $2,000,000 total costs **Research Level 2** $3,200,000 total costs Maximum POP is **4 years**

Preproposal Due: August 19, 2026

Full Application Due: November 18, 2026

Peer Review: January 2027

Programmatic Review: March 2027

ORP Products

SPRINT® Peripheral Nerve Stimulation System

- **Product:** Non-opioid pain relief device is on the market (now a Medtronic product)
- **Indications:** Phantom limb pain, neuroma pain in amputees, orthopaedic trauma pain, post-operative knee pain, back pain, and more
- **Funding:** ORP, PRMRP, JWMRP, SBIR
- https://www.sprpainrelief.com/indications



- 80% decrease in opioid use and sustained pain relief
- > 11,000 patients treated commercially to date

Vancomycin Powder

- **Product:** FDA approved antibiotic lyophilized into a powder for site-specific application to prevent infection
- **Indication:** Deep surgical site gram-positive infections
- **Funding:** ORP, JWMRP
- Systemic administration of antibiotics is less effective in patients with compromised blood supply and may cause systemic toxicity
- Locally applied vancomycin powder is now standard of care for treatment of orthopaedic fractures at high risk of infection

Studying Unique Populations

The orthopaedic field is **VAST**, including topics in training, prevention, tissue engineering, pain control, surgical techniques and care, comorbid injuries/conditions, rehabilitation, orthotics, prosthetics, and many more. The study populations, therefore, are varied and unique.

- Active-duty Service Members
- Veterans
- Very specific injury populations
  - Premenopausal females 10-years post-anterior cruciate ligament (ACL) reconstruction
  - Military Service Members with non-operative shoulder injuries
  - Military amputees with transtibial or transfemoral prostheses
  - Patients with fracture-related infection
  - Patients recovering from surgically repaired Achilles tendons
  - Military Service Members suffering from patellofemoral pain (i.e., knee pain)
- Acute trauma injury populations requiring time sensitive emergency treatment (Exception from Informed Consent, EFIC)

Emergency Study Considerations

- DOD Research Consent requirements (Title 10 U.S.C. Section 980)
- FDA consent waiver (21 CFR § 50.24)
- Local IRB requirements
- Timeline considerations
- Read FOA carefully
- Consult with OHRO



Strategies for Success

- ✓ **Relevance**
  - » Address program-specific goals
  - » **Align** the proposed work with specific guidance from the announcement
- ✓ **Impact**
  - » Propose **solutions** to important problems or gaps
  - » Clearly articulate translatability – how will this work **make a difference**?
- ✓ **Innovation**
  - » Provide clear rationale if proposing to test new, potentially high-risk ideas or use novel approaches
- ✓ **Feasibility**
  - » Justify a technically sound plan with clear approaches for contingencies
  - » Include evidence of appropriate **expertise**, such as collaboration, consultants, etc.
  - » Ensure to **appropriately power** the study for the proposed research outcome
  - » Demonstrate **availability** and **access** to critical resources, reagents, and/or subject populations



Strategies for Success, cont'd

- ✓ **Planning/Timelines**
  - » Include and allow adequate time in project plan for **regulatory approvals** if required
  - » For multi-organizational efforts, show a clear plan for **coordination** and communication
  - » For DOW collaborations, understand rules and plan for differences in funding process
- ✓ **Grantsmanship**
  - » Explain the proposed work with **clarity, unburdened** by jargon
  - » Understand the different audiences of the peer and programmatic reviews and **communicate** the potential impact effectively
  - » Review application documents carefully before submission – enlist experienced colleagues to help
  - » Don't break the rules for deadlines or requirements – **be compliant**

Journey of an Application Videos

Learn more about different funding opportunities, where CDMRP posts opportunities, and how to start the application process once you've found the opportunity most appropriate for your research.

Follow the journey of your application through the two-tier application review process and see how programs make funding recommendations.

For more information, please visit:

cdmrp.health.mil

Defense Health Program Science & Technology: Priorities and Opportunities

Emma Gregory, Science & Technology Portfolio Management,
Defense Health Agency

04 AUG 2026

DHA Research, Development & Acquisition System

Strategic Framework: National Defense Strategy, Component Strategic Documents, ASW (Health Affairs) Strategy and Guidance, and JSS CONOPs.

REQUIREMENTS (MANAGERS)

Joint Gaps & Requirements; SMG Priorities

Mission Owners/Users (Requirements Generators)

COMBATANT COMMANDS

Military Departments

Military Treatment Facilities

Research, Development, and Acquisition

Research (Science & Technology)
Who: DHA S&T
What: Manage risk, shape concepts & accelerate demonstration/transition of novel military capabilities

FUNDING: RDT&E 6.1 – 6.3, 6.6

S&T Outputs

Knowledge/ Non-Materiel Transition
Who: Centers of Excellence, Clinical Communities, Joint Trauma System, Public Health, Training & Education
What: Policies & Guidelines – Clinical Practice and/or Patient Care, Force Health Protection

S&T Outputs

Acquisition (Materiel Development & Commercial Solutions)
Who: DHA PAEs and Service PAEs
What: Acquisition and Fielding Decisions for materiel products (timeline, cost-effective delivery & sustainment of products & services); Industry transitions for commercialization

FUNDING: RDT&E 6.4, 6.5, 6.7, PROC, O&M

External Partners
- Industry
- Academia
- Other Government Agencies

Joint Medical Capabilities

- Services
- IM/IT Solutions
- Products – Drugs, Vaccines, Blood Products
- Supplies
- Equipment/Devices
- Knowledge Products

Continuous Feedback

DHP S&T: Research Scope

Defense Health Program (DHP) Science & Technology (S&T) includes the appropriation for RDT&E Budget Activities (BA) 6.1-6.3 (Basic Research, Applied Research, Advanced Technology Development):

- Medical research delivering knowledge or technology to develop materiel solutions relating to preventing, stabilizing, preserving, repairing, and/or resolving diseases or injuries affecting Warfighters across military operational environments
- Medical research addressing Joint medical capability requirements or gaps
- Research that is operationally relevant, transition-oriented, traceable to clinical practice, informs military doctrine, and/or informs health or product development



- Prioritized investments to target highest priority Joint medical capability gaps & requirements
- Deliberate strategy implementation plans with clearly articulated S&T deliverables, timelines, and cost

DHA S&T Strategic Research Plans: Solution Delivery Approach

Strategic Research Plans (SRPs): *S&T priorities based on assessments of current and future medical and operational needs and existing research gaps of the military medical community*

Roadmaps: *Programs to deliver SRP-derived S&T solutions aligned to validated Service Medical Group (SMG) priorities. 32 funded in FY27*

SRPs are posted on health.mil

POM27 DHP GDF S&T: SMG Category Alignment*

Roadmaps aligned to SMG gap categories in lieu of UNCLASS SMG list

- *93% of FY27 DHP GDF S&T Funding aligned to "high priority" SMG gaps*
- *100% of "high priority" SMG gaps within S&T solution space addressed by one or more SRP Roadmap*



*Source: DHP GDF FY27 Decision Brief (DAD S&T Approved June 2026)

Combat Casualty Care Roadmaps

Solutions for the acute & early management of combat-related trauma, including point of injury, prolonged & en-route care.

Immediate Casualty Care

Point-of-need Blood Products:
Blood and blood products to restore blood volume and restore oxygen-carrying and clotting capacity

Hemorrhage Solutions:
Products to rapidly stop internal and external bleeding, and to reliably obtain vascular access

Resuscitative Management:
Products to manage and triage wounded servicemembers, and to prevent or treat shock

Medical Care in Operational Environments

Complex Wound Stabilization:
Products to treat burns and other complex injuries, including wound repair and burn infections

Combined Injury Treatment:
Products to treat traumatic injuries, including kidney, lung, and other organ injuries

Patient Movement

Clinical Transport Capabilities:
Products to efficiently and safely transport injured servicemembers without interrupting treatment

SMG Category Legend

- Blood
- Patient Movement
- Prolonged/Delayed Evacuation Care

Military Infectious Diseases Roadmaps

Solutions for the prevention and treatment of military-relevant infectious diseases, to include combat-associated wound infections.

Prevent

Combat Wound Infections:
Broad-spectrum, point-of-injury antimicrobial products

Emerging/Endemic Diseases:
Products to protect against Dengue, CCHF and Lassa infections

Bacterial Diarrheal Disease:
Products with broad spectrum antibacterial coverage

Treat

Combat Wound Infections:
Bacterial wound infection treatments, including drug-resistant infections

Sepsis After Wound Infection:
Products to treat severe wound infections and septic disease

Emerging/Endemic Diseases:
Products to treat Dengue, CCHF, Lassa and Hantavirus infections

SMG Category Legend

- Prolonged/Delayed Evacuation Care
- Force Health Protection

Psychological Health Roadmaps

Solutions that maintain SM readiness, improve behavioral health diagnoses, and provide behavioral health interventions that enable rapid return-to-duty.

Sustain

Psychological Health Return-To-Duty Interventions:

Drug and non-drug interventions to treat behavioral health disorders and stop disorder progression

Assess

Psychological Health Decision Support & Diagnostics:

Products to accurately diagnose servicemembers and to direct them to the appropriate treatment resources

Optimize

Psychological Health Readiness & Performance Optimization:

Products to optimize readiness and resilience by ensuring effective post-exposure interventions and solutions

SMG Category Legend

Force Health Protection

Directed Energy & Radiological Health Roadmaps

Solutions for injuries and adverse health effects from exposure to ionizing radiation or non-ionizing radiation from directed energy.



SMG Category Legend

- Prolonged/Delayed Evacuation Care
- Force Health Protection
- Directed Energy

Environmental Exposures Roadmaps

Solutions for the wide range of chemical, physical, and environmental hazards that are part of the military environment.



Traumatic Brain Injury Roadmaps

Solutions to preserve, diagnose, or repair the physical, psychological, and cognitive status that affect a Warfighter's capacity to function adaptively in any environment.



SMG Category Legend

Brain Health

Musculoskeletal Injury Roadmaps

Solutions for the advancement of musculoskeletal injury management, across injury severity spectrums.



SMG Category Legend

Prolonged/Delayed Evacuation Care

Sensory System Roadmaps

Solutions for injury or illness to sensory systems, including research to characterize basic mechanisms and to advance assessment, diagnosis, monitoring, and treatment.

SMG Category Legend

Force Health Protection

DHA Funding Opportunities – BAAs, PAs, OIV

- **DHA Broad Agency Announcement (BAA)**
  The Defense Health Agency (DHA) Broad Agency Announcement (BAA) is a competitive solicitation procedure intended to solicit extramural research and development ideas. The BAA provides a general description of DHA S&T programs, including research areas of interest, general information, evaluation and selection criteria, and proposal/application preparation instructions. Research funded through the BAA is intended and expected to benefit and inform both military and civilian medical practice and knowledge. Research proposals/applications are sought from national, international, for-profit, non-profit, public, and private organizations. The BAA is a continuously open announcement; pre-proposals/pre-applications and proposals/applications may be submitted at any time throughout the 5-year period. https://grants.gov/search-results-detail/343725

- **Omnibus IV Multiple Award Military Medical Research & Development Indefinite Delivery/Indefinite Quantity Contract**
  Omnibus IV has a $10 billion ceiling and 10-year ordering period (5-year base & one 5-year option). Omnibus IV is the medical R&D go-to vehicle for DHA contracting. Learn more and find a link to the list of prime contract holders at https://www.health.mil/omnibus

- **Medical Technology Enterprise Consortium (MTEC)**
  The MTEC releases Request for Proposals (RPPs), based on topics from DHA S&T programs, for range of medical prototype technological and knowledge solutions https://mtec-sc.org/solicitations

Innovation Funding Opportunities – SBIR/STTR

DHA Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Programs

- Congressionally mandated to increase participation of U.S. small businesses in federal R&D
- Enables small US businesses to engage in **high-risk medical Combat Support Agency R&D** with the potential for dual use commercialization and equipping warfighters
- FY26 Funding: $57M SBIR; $8M STTR
- DHA topic areas: combat casualty care, directed energy health effects, environmental exposures, military infectious diseases, musculoskeletal injury, psychological health, sensory systems, and traumatic brain injury.
  - **SBIR·STTR website (sbir.gov)** SBA policy directives, award data, and state-based proposal assistance coordinators
  - **Defense SBIR/STTR Innovation Portal (dodsbirsttr.mil**) DoD SBIR/STTR broad agency announcements, topic Q&A, and email list registration for updates
  - **DHA SBIR/STTR information page (health.mil/SBIRSTTR)**
- Contact:
  - Mr. JR Myers, Project Manager, james.r.myers38.civ@health.mil
  - Ms. Colleen Gibney, Deputy Project Manager, colleen.n.gibney.civ@health.mil

Additional Information

- For inquiries and to request Strategic Research Plans, please contact the DHA STPM Mailbox: dha.ncr.j-9.mbx.stmp@health.mil

DHA Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Programs - Overview and Opportunities

J.R. Myers, DHA SBIR Project Manager

4 Aug 2026

Disclaimer

The presenter has no conflicts to report. The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Defense Health Agency, Department of War, nor the U.S. Government.

What are the SBIR & STTR Programs?

- **Federal government-wide**, the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are convened by the Small Business Administration (SBA) and designed to:
  - Stimulate technological innovation
  - Strengthen the role of small businesses in meeting government research and development (R&D) needs
  - Increase the commercial application of government-supported R&D
- **DoW services and components** receive program governance for DoW as a participating agency through OUSW(R&E) Office of Small Business Innovation (OSBI) https://www.defensesbirsttr.mil/SBIR-STTR/Program/
- SBA's Policy Directive may be found here: https://www.sbir.gov/about/policies

New 5-year SBIR/STTR Reauthorization!

Requirements and Eligibility

SBIR

- Small businesses must employ **500 or fewer employees**
- Firms must be at least **51%** owned and controlled by U.S. individuals
- A minimum of **2/3 of Phase I** and **1/2 of Phase II** work must be performed by the small business
- The Principal Investigator's **primary employment** must be with the small business—important and enforced

STTR

- Same size and ownership rules as SBIR
- Requires cooperative R&D with a U.S. research institution (RI)
  - **Minimum 40%** by small business
  - **Minimum 30%** by research institution subcontractor

DHA SBIR/STTR and Other Medical Funders

- DHA is the largest military medical SBIR/STTR seed funder
  - **FY26 SBIR: $57,488,000**
  - **FY26 STTR: $8,091,000**
- Other DoW medical SBIR/STTR topic sources:
  - **Air Force, Army, Navy, CBD, DARPA, DLA, DTRA,** and **SOCOM**
- Non-DoW medical SBIR/STTR solicitation sources:
  - **DHS, HHS (largest-NIH, CDC, ARPA-H, etc.), NASA, NSF**, and **DoC (NIST/NOAA)**
- Note that the SBIR/STTR mechanism is portable – for example, past NSF work could be of interest to DoW/DHA if highly successful!

DHA SBIR/STTR Topic Areas

- SBIR/STTR topics primarily fund DHA S&T priorities under the following categories:

1. Combat Casualty Care
2. DoW Working Dog
3. Environmental Exposures
4. Military Infectious Diseases
5. Musculoskeletal Injury
6. Psychological Health
7. Sensory Systems
8. Traumatic Brain Injury

https://www.health.mil/Military-Health-Topics/Research-and-Innovation/DHA-Research-and-Engineering-Directorate/Science-and-Technology-Portfolio-Management-Division

Revised 2026 SBIR/STTR BAA Schedule

- DoW will publish new topics on the first Wednesday of each month on the DSIP Portal (link below)
- Sign up to the DSIP Listserv to receive all new topic announcements
  - Best way to track DHA and other medical topics



https://www.dodsbirsttr.mil/submissions/login

DHA SBIR/STTR Funding Pathway

Phase II Enhancement – 1:1 match with qualified Phase III investment up to $700K – 1 year added

Funding Pathway Details

- **Phase I proof of concept**
  - Test feasibility of the innovation while de-risking the initial prototype plan
- **Phase II prototype development**
  - Refine the prototype; drive down technical, regulatory, and adoption risks
- **Direct to Phase II**
  - Prior art (not previously funded by Federal SBIR/STTR) enables the small business to skip Phase I and move directly to rapid prototyping
- **Phase II Enhancement**
  - Additional award modification of up to $650K based upon 1:1 Phase III customer match to increase TRL levels and speed time to market
- **Phase III Planning Assistance**
  - DHA SBIR/STTR provides Phase III readiness training and personalized plan assistance from the start of the Phase I award

Resource Links for Small Businesses

- **Defense SBIR/STTR Innovation Portal (DSIP):** Access Broad Agency Announcements (BAAs), job aids, templates, and tutorials https://www.dodsbirsttr.mil/submissions/login
- **SBA Federal and State Technology (FAST) Partnership Program:** Builds outreach pipelines and provides technical and business assistance https://www.sbir.gov/community/fast
- **APEX Accelerators:** Offers no-cost guidance and support to succeed in the DoW marketplace https://www.apexaccelerators.us/#/
- **Project Spectrum:** Provides cybersecurity training and resources to meet compliance requirements https://www.projectspectrum.io/#/

Key Takeaways

- Register on DSIP (BAA announcements, proposal submissions, important program updates)
- Ask questions during SBIR/STTR BAA topic pre-release
- Read all Component instructions carefully
- Plan ahead and submit proposal early
- Visit DoW and SBA websites for helpful tutorials

Thank you

The future of military medical capability innovation depends on small businesses committed to delivering sustainable and meaningful impact to the Warfighter. You are greatly needed, and our office is here to support your efforts.

Understanding Award Mechanisms and Other Advice from the Defense Health Agency Contracting Activity (DHACA)

Ms. Amanda L. Best, Contracting/Agreements Officer
Defense Health Agency Contracting Activity (R&D)
Fort Detrick MD
Amanda.L.Best7.civ@health.mil

MHSRS
August 2026

The views expressed in this presentation are of the authors and may not necessarily be endorsed by the Defense Health Agency

Briefing Overview

- Defense Health Agency Contracting Activity (DHACA)
  - Who are we - How we support the R&D Mission (Our Role)
  - Who do we support – Our Primary and Secondary Customers
- Execution Mechanisms Overview and Solicitation Sources
- Contractual Execution Mechanisms Specifics
  - Grants/Cooperative Agreements
  - OTA's
    - ✓ pOTA's
      - MTEC and Stand-Alone
    - ✓ rOTA's
  - SBIRs
- FAR Contracts
- Differences
- DHACA Highlights – Why we are successful
- Resources

What is DHACA R&D

- DHACA R&D is the Research Contracting Arm of the Defense Health Agency
- DHACA R&D FY25 Annual Execution (Dollars): $1.3B
- DHACA R&D Supports Predominantly the Defense Health Agency Research and Development, Research and Engineering, and the U.S. Army Medical Research and Development Command, as well as some other DHA Entities and External Partners
- DHACA R&D Specializes in R&D (FAR-Based) Contracts, Grants, Cooperative Agreements, SBIR's and Research & Prototype Other Transaction Agreements to Deliver, and Sustain Medical Capabilities, Advance Public Health Globally, and Enhance Warfighter Readiness

DHACA R&D's Divisions Primary Customers

- Grants Division (Incl OTAs)
  - CDMRP
  - WRAIR
  - Military Health Research Program

- Contracts Division (Incl OTAs)
  - DHA (R&E and R&D)
  - DoW Labs (WRAIR, USAMRIID, ISR, ICD)
  - PAE – Medical Products
  - SBIRs
  - SOCOM
  - Army
  - Navy
  - Air Force

Award Mechanisms and Primary Sources

- **Grants and Cooperative Agreements**
  - Defined: Grants and cooperative agreements are federal funding mechanisms used to provide financial assistance, with the key difference being the level of federal involvement in the project (Grant – Minimal, Cooperative Agreement – Substantial). Also, public purpose
  - Primary Solicitation Mechanisms: Broad Agency Announcement (BAA), Program Announcements
- **Other Transaction Agreements (OTAs) for Prototype (pOTA) and Research (rOTA)**
  - Defined: Other Transaction Authority (OTA's) agreements provide an alternative approach to Government (i.e. FAR) procurements, offering more flexibility and innovation compared to traditional FAR contracts. OTAs allow certain federal agencies to engage in non-traditional agreements, primarily for research and development purposes. rOTA Authorizes basic, applied, and advanced research projects (Mandatory Cost Share) whereas pOTA Authorizes the acquisition or development of prototypes (Cost Share Depends)
  - Primary Solicitation Mechanism: MTEC RPP, Broad Agency Announcement (BAA)

Award Mechanisms and Primary Sources (continued)

- **Small Business Innovation Research (SBIR) Program**
  - Defined: A competitive federal grant provided by the U.S. Small Business Administration (SBA) through the Small Business Innovation Research (SBIR) program. It is designed to help small businesses—especially those with innovative ideas—participate in federal research and development (R&D) and bring those innovations to market. Referred to as "America's Seed Fund" for technology-focused entrepreneurs, startups, and small businesses
  - Primary Solicitation Mechanism: DoW SBIR/STTR Innovation Portal (DSIP), Broad Agency Announcement and Commercial Solutions Opening (CSO)

- **FAR Based Contracts for R&D**
  - Defined: FAR contracts are governed by the Federal Acquisition Regulation, a comprehensive set of rules and guidelines designed to regulate federal government procurement. These contracts are primarily used by Government agencies to acquire goods and services. They are characterized by stringent terms and conditions that ensure compliance with legal and regulatory requirements.
  - Primary Solicitation Mechanism: Broad Agency Announcement (BAA), Targeted Solicitation (SAM.gov)

Comparison of DHACA's Contracting Execution Instruments

Instrument	Statute/Guide/ Policy	Teaming	IP/Data Rights	Funding Type	Dialogue/ Negotiation	Advantage/ Disadvantage
Grant	DoDGAR	Prime/Sub Arrangement	Favor the Recipient	Primarily Applied Research	Typically Structured	A – Simplified Mgt. D – Limited Oversight
Cooperative Agreement	DoDGAR	Prime/Sub Arrangement	Favor the Recipient	Multiple R&D Funding Categories	Typically Open	A – Heavy Oversight D – Higher Gov't Risk
FAR Contract	FAR / DFAR	Prime/Sub Small Business Subs Encouraged	Standard FAR Clauses	Basic, Applied and Advanced Funding	Very Structured (in writing)	A – Structured D – No Open Dialogue
SBIR	15 U.S. Code § 638; SBIR Policy Directive	Encouraged (Participation Limits – SBA Rules)	SBIR Data Rights Clauses (20 Yrs)	SBIR Funds (Phase I and II), Phase III non-SBIR Dept Funds	Structured	A – Streamlined A – Commercialization D - Limited to Small Businesses
pOTA	10 USC 4022; OTA Guide	Generally Prime/Sub Arrangement	Asserted by Either Partner and Negotiated	Applied and Advanced Funds	Open (solicitation and Award)	A – Open Dialogue A - Non-Traditionals D – Single Purpose
rOTA	10 USC 4021; OTA Guide	Co-managed with Articles of Collaboration	Asserted by Either Party and Negotiated	Basic, Applied and Advanced Funding	Open (solicitation and Award)	A – Open Dialogue A - Non-Traditionals D – Cost Share Requirements

DHACA Success Stories

- DHACA is highly specialized, highly structured "gatekeeper" of military medicine supporting prestigious programs such as CDMRP, the DHA SBIR Program, forward leaning use of Other Transaction Agreements (OTA) authority

- MTEC Prototype OTA
  - DHACA R&D's Prototype Consortium OTA
    - ✓ $1.5B Funded Awards – Advancing Medical Technology and Innovation
    - ✓ 700+ Members (95% Non-Traditionals)

- DHA's OMNIBUS IV Contract Vehicle
  - DHA's 10 Year $10B R&D Service/Support IDIQ – Currently 53 Task Orders awarded with a total value of over $634M
  - Premier mechanism for DoW agencies to procure professional, technical, and scientific solutions to advance military medical research, force health readiness, performance, and rehabilitation

- SBIR Program
  - Unparalleled SMEs
  - Highly Successful Execution and Advancement Track Record

- Research OTA (rOTAs) "Team Approach" – OTA Subject Matter Expertise Awarding Multiple Stand-Alone rOTAs
  - Experience in Awarding Multiple rOTAs Expanding DHACA R&D Broad Scope of Execution Vehicles in Support of the Warfighter. Legal SME's Team with Contracting are Highly Regarded in Areas of IP and Cost-Share Negotiations

Key Websites for Additional Information

- DHACA
  - https://www.dha.mil/Working-with-DHA

- MRDC BAA
- https://simpler.grants.gov/search?utm_source=Grants.gov - search: DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD

- SBIR
  - https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/
  - https://www.dodsbirsttr.mil/submissions/login

- SAM.GOV
  - https://sam.gov/opportunities/federal

- MTEC
  - https://mtec-sc.org/

Question & Answer Session